Home›Stock Screener›Nath Bio-Genes›Financial Statements

Nath Bio-Genes Complete Financial Statements

4 Years of Data
2025 - 2022

In FY2025, Nath Bio-Genes (NATHBIOGEN) reported revenue ₹48 Cr, net profit ₹5 Cr and EPS ₹2.53, with a net profit margin of 10.4% and ROE of 0.8%. Full financial statements from FY2022 to FY2025 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Nath Bio-Genes stock price NSE .

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 10.42% 2025 data
EBITDA Margin 20.83% 2025 data
Operating Margin 14.00% 2025 data
Return on Assets 0.49% 2025 data
Return on Equity 0.78% 2025 data

Balance Sheet Ratios

Current Ratio 40.59 2025 data
Equity Ratio 62.77% 2025 data
Asset Turnover 0.05 2025 data

NATHBIOGEN Revenue, Net Profit & EBITDA — Year-on-Year Growth

NATHBIOGEN YoY (Sept 2024 vs Sept 2025) — revenue +50.0%, net profit +400.0%, EBITDA +100.0%, expenses +40.7%. See NATHBIOGEN book value to compare market price against book value per share.

Revenue Growth
+50.0%
Year-over-Year
Net Profit Growth
+400.0%
Year-over-Year
EBITDA Growth
+100.0%
Year-over-Year
Expense Growth
+40.7%
Year-over-Year
Assets Growth
+16.6%
Year-over-Year
Equity Growth
+5.6%
Year-over-Year
Operating Cash Flow Growth
-76.0%
Year-over-Year
Investing Cash Flow Growth
+85.2%
Year-over-Year
Financing Cash Flow Growth
+75.0%
Year-over-Year

NATHBIOGEN Income Statement — Revenue, EBITDA & Net Profit

Nath Bio-Genes revenue ₹48 Cr, EBITDA ₹10 Cr, net profit ₹5 Cr, EPS ₹2.53 (2025) — net profit margin 10.4%. Check NATHBIOGEN enterprise value to track the company's total market size over time.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Mar 2022 Jun 2022 Dec 2022
Revenue 48 56 288 70 32 44 244 37 23 45 235 34 22 28 209 25
Expenses 38 52 245 62 27 39 207 29 18 41 198 26 17 137 175 20
EBITDA 10 5 42 8 5 5 37 9 5 4 37 8 5 -109 35 6
Operating Profit Margin % 14.00% 1.00% 13.00% 5.00% 15.00% 9.00% 15.00% 22.00% 22.00% 9.00% 16.00% 18.00% 22.00% -405.00% 16.00% 22.00%
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Interest 4 1 3 5 3 1 2 4 2 2 3 3 3 3 3 3
Profit Before Tax 6 2 38 3 1 3 34 4 2 2 34 5 2 -113 31 2
Tax 1 1 1 1 0 1 0 1 0 0 0 1 0 4 0 1
Net Profit 5 2 37 2 1 3 33 3 2 1 33 4 2 -116 31 1
Earnings Per Share (₹) 2.53 0.42 19.58 0.84 0.53 1.87 17.49 1.33 0.86 0.77 17.59 2.02 0.77 -61.22 16.18 0.71

NATHBIOGEN Balance Sheet — Assets, Liabilities & Shareholders' Equity

NATHBIOGEN total assets ₹1,026 Cr, total equity ₹644 Cr, total liabilities ₹ Cr (2025) — ROE 0.8%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022
ASSETS
Total Assets 1,026 880 793 740
Current Assets 690 572 521 468
Fixed Assets 250 250 244 245
Capital Work in Progress 0 0 0 0
Investments 6 6 5 5
Other Assets 770 625 543 490
LIABILITIES
Total Liabilities
Current Liabilities 17 8 3 3
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 644 610 573 542
Share Capital 19 19 19 19
Reserves & Surplus 625 591 554 523

NATHBIOGEN Cash Flow Statement — Operating, Investing & Financing

Nath Bio-Genes operating cash flow ₹18 Cr, investing ₹-4 Cr, financing ₹-2 Cr, net cash flow ₹12 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022
Operating Activities 18 75 38 17
Investing Activities -4 -27 -3 -20
Financing Activities -2 -8 -2 -22
Net Cash Flow 12 39 34 -25